Jim Cramer's Stop Trading: Shares of Acorda Therapeutics Deserve This Move Up

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, called Ron Cohen, the CEO of Acorda Therapeutics (ACOR) , "one of the greatest CEOs" in the biotech industry.  

The company's latest acquisition of Civitas for $525 million will help buildout Acorda's portfolio of treatments. 

Civitas is "apparently having great success" with its Parkinson's treatment, which is in Phase 3 trials, he said. 

Shares of Acorda Therapeutics are up 18% and are "correct in going higher," Cramer concluded, adding that the company is "remarkable."

 
-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Earnings Season Is Simply Out of Control Madness - How Are You Surviving?

Earnings Season Is Simply Out of Control Madness - How Are You Surviving?

Why Ether and Ripple -- But Not Bitcoin -- Prices Might Come Under Pressure Soon

Why Ether and Ripple -- But Not Bitcoin -- Prices Might Come Under Pressure Soon

Daily Chatter: Here's Where the Markets Stand After Tuesday's Beating

Daily Chatter: Here's Where the Markets Stand After Tuesday's Beating

3 New Investing Myths That Must Be Busted

3 New Investing Myths That Must Be Busted

Why a Global Stock Market Crash Is Coming

Why a Global Stock Market Crash Is Coming